scholarly journals Therapeutic Potential of Montelukast, Cysteinyl Leukotriene Receptor 1 Antagonist, for Aortic Aneurysm

2019 ◽  
Vol 58 (6) ◽  
pp. e419
Author(s):  
Yohei Kawai ◽  
Yuji Narita ◽  
Aika Ogata ◽  
Akihiko Usui ◽  
Kimihiro Komori
Keyword(s):  
Aortic Aneurysm ◽  
Therapeutic Potential ◽  
Cysteinyl Leukotriene ◽  
Leukotriene Receptor ◽  
Cysteinyl Leukotriene Receptor

scholarly journals Possible Therapeutic Potential of Cysteinyl Leukotriene Receptor Antagonist Montelukast in Treatment of SARS-CoV-2-Induced COVID-19

Pharmacology ◽  
2021 ◽  
Vol 106 (9-10) ◽  
pp. 469-476
Author(s):  
Mangaldeep Dey ◽  
Rakesh Kumar Singh
Keyword(s):  
Receptor Antagonist ◽  
Clinical Symptoms ◽  
Therapeutic Potential ◽  
Lung Pathology ◽  
Cysteinyl Leukotriene ◽  
Production Improvement ◽  
Leukotriene Receptor ◽  
Cysteinyl Leukotriene Receptor ◽  
Clinical Potential

<b><i>Background:</i></b> The coronavirus disease-19 (COVID-19) pandemic is a serious devastating disease and has posed a global health emergency. So far, there is not any specific therapy approved till date to control the clinical symptoms of the disease. Remdesivir has been approved by the FDA as an emergency clinical therapy. But it may not be effective alone to control the disease as it can only control the viral replication in the host. <b><i>Summary:</i></b> This article summarizes the possible therapeutic potential and benefits of using montelukast, a cysteinyl leukotriene 1 (CysLT<sub>1</sub>) receptor antagonist, to control COVID-19 pathophysiology. Montelukast has shown anti-inflammatory effects, reduced cytokine production, improvement in post-infection cough production and other lung complications. <b><i>Key Messages:</i></b> Recent reports clearly indicate a distinct role of CysLT-regulated cytokines and immunological signaling in COVID-19. Thus, montelukast may have a clinical potential to control lung pathology during COVID-19.

scholarly journals LTD4 and TGF-β1 Induce the Expression of Metalloproteinase-1 in Chronic Rhinosinusitis via a Cysteinyl Leukotriene Receptor 1-Related Mechanism

Sinusitis ◽  
2016 ◽  
Vol 1 (1) ◽  
pp. 65-75
Author(s):  
Rogerio Pezato ◽  
Cindy Claeys ◽  
Gabriele Holtappels ◽  
Claus Bachert ◽  
Claudina Pérez-Novo
Keyword(s):  
Chronic Rhinosinusitis ◽  
Cysteinyl Leukotriene ◽  
Leukotriene Receptor ◽  
Cysteinyl Leukotriene Receptor ◽  
Tgf Β1
Sign in / Sign up

Export Citation Format

Share Document